| Literature DB >> 33140861 |
Yan-Mei Chen1, Yuanting Zheng1, Ying Yu1, Yunzhi Wang1, Qingxia Huang1, Feng Qian1, Lei Sun1, Zhi-Gang Song1, Ziyin Chen1, Jinwen Feng1, Yanpeng An1, Jingcheng Yang1, Zhenqiang Su1, Shanyue Sun1, Fahui Dai1, Qinsheng Chen1, Qinwei Lu1, Pengcheng Li1, Yun Ling1, Zhong Yang1, Huiru Tang1, Leming Shi1, Li Jin1, Edward C Holmes2, Chen Ding1, Tong-Yu Zhu1, Yong-Zhen Zhang1.
Abstract
COVID-19 is characterized by dysregulated immune responses, metabolic dysfunction and adverse effects on the function of multiple organs. To understand host responses to COVID-19 pathophysiology, we combined transcriptomics, proteomics, and metabolomics to identify molecular markers in peripheral blood and plasma samples of 66 COVID-19-infected patients experiencing a range of disease severities and 17 healthy controls. A large number of expressed genes, proteins, metabolites, and extracellular RNAs (exRNAs) exhibit strong associations with various clinical parameters. Multiple sets of tissue-specific proteins and exRNAs varied significantly in both mild and severe patients suggesting a potential impact on tissue function. Chronic activation of neutrophils, IFN-I signaling, and a high level of inflammatory cytokines were observed in patients with severe disease progression. In contrast, COVID-19-infected patients experiencing milder disease symptoms showed robust T-cell responses. Finally, we identified genes, proteins, and exRNAs as potential biomarkers that might assist in predicting the prognosis of SARS-CoV-2 infection. These data refine our understanding of the pathophysiology and clinical progress of COVID-19.Entities:
Keywords: COVID-19 pathophysiology; SARS-CoV-2; immunopathogenesis; multi-omics; multiple organ damage
Mesh:
Substances:
Year: 2020 PMID: 33140861 PMCID: PMC7737620 DOI: 10.15252/embj.2020105896
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 14.012